Synergy Life Science Partner
Description
Synergy Life Science Partners is a distinguished venture capital firm based in Portola Valley, California, specializing in financing early-stage medical device and combination product companies. The firm is co-founded and led by Fred Khosravi, a seasoned entrepreneur and investor with a deep background in the medical technology sector. Khosravi's operational expertise, including his prior role as founder and CEO of AccessClosure, which was acquired by Cardinal Health for $320 million, underpins the firm's hands-on approach to supporting its portfolio companies.
Synergy Life Science Partners manages multiple funds, including Synergy Life Science Partners Fund I, L.P. and Fund II, L.P., each targeting a fund size of $100 million. This capital is strategically deployed to support the development and commercialization of innovative medical technologies that address significant unmet clinical needs. The firm's investment philosophy emphasizes identifying companies with strong intellectual property, clear regulatory pathways, and the potential for substantial market impact, often providing not just capital but also strategic guidance and access to a vast network within the healthcare industry.
The firm boasts an impressive track record of successful exits, demonstrating its acumen in identifying and nurturing high-potential ventures. Notable portfolio companies that have achieved significant milestones include Inari Medical, PulmonX, and Shockwave Medical, all of which have gone public. Other successful exits include the acquisition of CardioDx by Clinical Reference Laboratory and VytronUS by Boston Scientific. Synergy Life Science Partners' consistent success underscores its specialized focus and the value of its experienced leadership in navigating the complex landscape of medical device innovation.
Investor Profile
Synergy Life Science Partner has backed more than 20 startups, with 0 new investments in the last 12 months alone. The firm has led 3 rounds, about 15% of its total and boasts 6 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Medical Device, Health Care, Biotechnology.
- Typical check size: $2M – $10M.
Stage Focus
- Series B (25%)
- Series C (20%)
- Series Unknown (15%)
- Post Ipo Equity (10%)
- Series D (10%)
- Series F (5%)
- Series E (5%)
- Private Equity (5%)
- Series A (5%)
Country Focus
- United States (100%)
Industry Focus
- Medical Device
- Health Care
- Biotechnology
- Therapeutics
- Health Diagnostics
- Mhealth
- Wearables
- Robotics
- Enterprise Software
- Manufacturing
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
